Case Report: A novel de novo variant of COL1A1 in fetal genetic osteogenesis imperfecta

• Published in: Frontiers in endocrinology (Lausanne) 2023, Vol.14, p.1267252-1267252
• Main Authors: Mai, Qiuyan, Han, Ruining, Chen, Yinlong, Shen, Ke, Wang, Shimin, Zheng, Qingliang
• Format: Article
• Language: English
• Subjects: COL1A1; Collagen Type I - genetics; Collagen Type I, alpha 1 Chain; de novo; DNA; Humans; osteogenesis imperfecta; Osteogenesis Imperfecta - genetics; Osteogenesis Imperfecta - pathology; type I collagen; whole exome sequencing
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2023.1267252

Osteogenesis imperfecta (OI) is a rare genetic disorder. Clinical severity is heterogeneous. The purpose of this study was to investigate the genetic characteristics of a fetus with OI by whole exome sequencing (WES) and identify the cause of the disease. In this study, a fetus with osteogenic dysplasia was referred to our hospital. DNA was extracted from the aborted fetal tissue and peripheral blood of the parents. To identify the pathogenic genes, we conducted the trio-WES using DNA. A variant in the gene is suspected to be the cause of the OI phenotype. We used Sanger sequencing for validation and various bioinformatics methods (such as SIFT, PolyPhen2, Mutation Taster, conservative analysis, SWISS Model, glycosylation site prediction, and I-Mutant 2.0) for analysis. Both WES and Sanger sequencing identified a novel variant of (c. 1309G>A, p. Gly437Ser) in a fetus with OI. Bioinformatic analysis showed that the affected residue, p. Gly437, was highly conserved in multiple species and predicted that the variant was deleterious and may have an impact on protein function. This variant is present in highly conserved glycine residues of Gly-X-Y sequence repeats of the triple helical region of the collagen type I α chain, which may be the cause of OI. This study revealed that the c.1309G>A (p. Gly437Ser) variant in the gene may be the genetic cause of fetal OI in this case. The discovery of this variant enriched the variation spectrum of OI. WES improves the accurate diagnosis of fetal OI, and doctors can provide patients with appropriate genetic counseling.